Neuroimmune Control of Allergic Immunity
Neuroimmune Control of Allergic Immunity
批准号:
10625256
负责人:
Caroline Lauren Sokol
金额:
$59.63万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-01 至 2026-05-31
关键词:
Afferent NeuronsAllergensAllergicAllergic DiseaseAntigensB-LymphocytesBacteriaBasophilsCCR8 geneCell CommunicationCell MaturationCell physiologyCellsCellular ImmunologyCellular NeurobiologyCutaneousDataDendritic CellsDendritic cell activationDermalDermisDetectionDevelopmentDiseaseEndowmentFoundationsGoalsHealthIgEImmuneImmune responseImmune systemImmunityImmunizationImmunologicsIn VitroInnate Immune ResponseInnate Immune SystemInterleukin-4LaboratoriesLicensingLymphoid CellMusNervous SystemNeuroimmuneNeuronsNeuropeptidesPapainPapayaPathway interactionsPatientsPeptide HydrolasesPlayPopulationPrevalenceProductionPruritusResearchRoleSensorySignal TransductionSkinSubstance PT-LymphocyteTRPV1 geneTestingTh2 CellsUnited StatesVenomsadaptive immune responsecell motilitychronic itchdraining lymph nodeenvironmental allergenexperiencefungusimmune activationimprovedin vivoinsightmast cellmigrationneurotransmitter releasenovelnovel therapeutic interventionnovel therapeuticspain sensationpreventprogramsrelease factorresponsesensortherapeutic developmenttool
中文摘要
项目摘要/摘要
启动变态反应免疫的一个中心悖论是,尽管树突状细胞对于
过敏免疫反应的启动,树突状细胞在体内被过敏原免疫激活,但不是
由过敏原直接在体外产生。这表明,另一个细胞可能作用于树突状细胞的上游,起到
最初的过敏原传感器。我们的长期目标是了解先天免疫系统是如何通过
过敏原启动过敏性免疫反应。鉴于40%的美国人口患有
一种或多种过敏性疾病,并且过敏性疾病的流行率在全球范围内继续增加,我们
认为有迫切的健康需要了解过敏性疾病是如何引发的。我们最近发现,
感觉神经元在体内和体外被变应原直接激活,导致P物质的释放
这通过其MRPGPRA1的表达激活了Th2偏斜树突状细胞的迁移。我们的中央
假设感觉神经元是过敏原的初始感受器,它们与先天的
免疫细胞既促进感觉神经元对变应原的反应性,又允许感觉神经元
启动过敏免疫反应。在详细描述涉及的感觉神经元的最新突破的基础上
在过敏原感知中,树突状细胞亚群对过敏原的反应,以及过敏偏斜的机制
树突状细胞的迁移,我们建议结合细胞免疫学和神经生物学的工具来获得
对促进过敏性免疫激活的神经免疫相互作用有基本的了解。使用这些
工具,我们建议在两个特定的目标中检验我们的中心假设:(1)确定
过敏原刺激的感觉神经元与树突状细胞相互作用并启动树突状细胞激活,以及(2)确定T是如何
细胞通过变应原控制感觉神经元的激活。目标1将研究感官之间的相互作用
神经元和树突状细胞,以及在这些相互作用中对P物质和MRGPRA1的需求。目标2
将阐述一种新的真皮T细胞亚群如何赋予或促进感觉的反应性
神经元对过敏原的反应。这些研究将为制定治疗策略奠定基础
预防初始过敏反应(目标1),治疗慢性瘙痒疾病(目标2),预防多发性过敏反应
既往有过敏性疾病的患者(目标1和2)。
英文摘要
Project Summary/Abstract
One central paradox in the initiation of allergic immunity is that although dendritic cells are necessary for the
initiation of allergic immune responses, dendritic cells are activated in vivo by allergen immunization, but not
directly in vitro by allergens. This indicates that another cell may act upstream of dendritic cells to act as the
initial allergen sensor. Our long-term goal is to understand how the innate immune system is activated by
allergens to initiate the allergic immune response. Given that 40% of the United States population suffers from
one or more allergic diseases and that the prevalence of allergic disease continues to increase worldwide, we
believe there is an urgent health need to understand how allergic diseases are initiated. We recently found that
sensory neurons are directly activated by allergens in vivo and in vitro, leading to the release of Substance P
that activates the migration of Th2-skewing dendritic cells through their expression of MRPGPRA1. Our central
hypothesis is that sensory neurons are the initial sensors of allergens and that their interactions with innate
immune cells both promote sensory neuronal responsiveness to allergens and allows sensory neurons to
initiate the allergic immune response. Building upon recent breakthroughs detailing sensory neurons involved
in allergen sensing, dendritic cell subsets that respond to allergens, and mechanisms of allergic-skewing
dendritic cell migration, we propose to integrate tools of cellular immunology and neurobiology to gain a
fundamental understanding of neuroimmune interactions that promote allergic immune activation. Using these
tools, we propose to test our central hypothesis in two specific aims: (1) determine the mechanisms by which
allergen-stimulated sensory neurons interact with and initiate dendritic cell activation, and (2) identify how T
cells control sensory neuron activation by allergens. Aim 1 will examine the interactions between sensory
neurons and dendritic cells, and the requirement for Substance P and MRGPRA1 in these interactions. Aim 2
will address how a novel subset of dermal T cells may endow or promote the responsiveness of sensory
neurons to allergens. These studies will lay the groundwork for the development of therapeutic strategies to
prevent initial allergic sensitization (Aim 1), treat chronic itch diseases (Aim 2), and prevent polysensitization in
patients with pre-existing allergic disease (Aims 1 & 2).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neuroimmune Control of Allergic Immunity
-
批准号:10786435
-
项目类别:
-
资助金额:$2.29万
-
财政年份:2023
-
负责人:Caroline Lauren Sokol
-
依托单位:
Age-Related Alterations in Neuro-Immune Recognition of Allergens
-
批准号:10373431
-
项目类别:
-
资助金额:$24.41万
-
财政年份:2022
-
负责人:Caroline Lauren Sokol
-
依托单位:
Age-Related Alterations in Neuro-Immune Recognition of Allergens
-
批准号:10559576
-
项目类别:
-
资助金额:$20.34万
-
财政年份:2022
-
负责人:Caroline Lauren Sokol
-
依托单位:
Neuroimmune Control of Allergic Immunity
-
批准号:10823390
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2021
-
负责人:Caroline Lauren Sokol
-
依托单位:
Neuroimmune Control of Allergic Immunity
-
批准号:10211590
-
项目类别:
-
资助金额:$59.63万
-
财政年份:2021
-
负责人:Caroline Lauren Sokol
-
依托单位:
Neuroimmune Control of Allergic Immunity
-
批准号:10362621
-
项目类别:
-
资助金额:$59.63万
-
财政年份:2021
-
负责人:Caroline Lauren Sokol
-
依托单位:
The Role of Innate Immune Cell Trafficking in Th2 Differentiation
-
批准号:9302656
-
项目类别:
-
资助金额:$20.09万
-
财政年份:2016
-
负责人:Caroline Lauren Sokol
-
依托单位:
The Role of Innate Immune Cell Trafficking in Th2 Differentiation
-
批准号:9923557
-
项目类别:
-
资助金额:$20.09万
-
财政年份:2016
-
负责人:Caroline Lauren Sokol
-
依托单位:
海外基金